SLC5A2 and chronic kidney disease: Positive renal and cardiovascular effects during the treatment of patients with diabetes and chronic kidney disease (CKD) have been demonstrated using SGLT2‐inhibitors such as empagliflozin and dapagliflozin, which are novel, recently approved antihyperglycemic drugs, inhibiting renal glucose reabsorption and increasing urinary glucose release [10, 11].